Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12 – 15, 2021.
All posters presented will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.
Chronic Hepatitis B
S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM)
Title: S-antigen Transport-inhibiting Oligonucleotide Polymers, (STOPSTM) Sequester Cellular Proteins to Reduce Hepatitis B Virus S-Antigen Expression and Increase Its Proteasomal Degradation
Publication Number: 845
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: C. Cheng Kao
Capsid Assembly Modulator (CAM)
Title: Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)
Publication Number: 843
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Ed Gane
Antisense Oligonucleotide (ASO)
Title: Best-in-Class Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Significantly Increase In Vivo Efficacy and Reduce Hepatotoxicity in Mice
Publication Number: 820
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Dinah Misner
Title: ALG-020572, a GalNAc-Conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B
Publication Number: 819
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Kusum Gupta
siRNA
Title: Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model
Publication Number: 831
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Jin Hong
Combinations
Title: Triple Combination of Anti-Hepatitis B Virus Drugs Demonstrates Synergistic Activity In Vitro
Publication Number: 852
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Hua Tan
NASH
Title: Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
Publication Number: 1932
Session Title: NAFLD and NASH: Therapeutics
Presenter: Kusum Gupta
Title: Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH
Publication Number: 1907
Session Title: NAFLD and NASH: Therapeutics
Presenter: Xuan Luong
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’s strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements”. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
